

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 under  
the Securities Exchange Act of 1934**

For the month ended November, 2012

**ICON plc**  
(Registrant's name)

0-29714  
(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland  
(Address of principal executive offices)

Brendan Brennan, CFO  
South County Business Park Leopardstown, Dublin 18, Ireland.  
Brendan.Brennan@iconplc.com  
0011-353-1-291-2000

(Name, telephone number, email and/or facsimile number and address of Company contact person)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes  No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 **N/A**

---

**EXHIBIT LIST**

Exhibit      Description

99.1            ICON plc Press Release issued November 29, 2012.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ICON plc**

Date: November 29, 2012

/s/ Brendan Brennan  
Brendan Brennan  
Chief Financial Officer

**Dr. Bruce Given notifies ICON that he will not seek a further term as Chairman of the Board**

DUBLIN--(BUSINESS WIRE)--November 29, 2012--**ICON plc. (NASDAQ:ICLR) (ISIN:IE0005711209)**, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Bruce Given, non-executive chairman of the board, has notified the company that it is his intention not to seek a second term as chairman when his current term expires on December 31<sup>st</sup> 2012. Dr. Given has served as ICON's chairman since 1<sup>st</sup> January 2010 and has been a member of the company's board of directors since 2004.

Dr. Given commented, "The time commitment for the chairman's role was increasingly challenging given my operational responsibilities outside of ICON. Having overseen a very successful transition in the executive leadership of the company, new strategic alliances, as well as a return to strong growth in revenues and earnings, I believe the timing is right for me to relinquish the chair."

On behalf of the board, Mr. Ciaran Murray, ICON CEO, commented, "I would like to thank Bruce for his leadership and support over the past three years in his role as chairman."

The board of directors will now initiate a process to select a new chairman, from among its members, to be appointed with effect from January 1<sup>st</sup> 2013.

The information contained in this release is as of 29<sup>th</sup> November 2012. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON's Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

---

## **About ICON plc:**

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 82 locations in 40 countries and has approximately 9,430 employees. Further information is available at [www.iconplc.com](http://www.iconplc.com).

ICON/ICLR-F

### **CONTACT:**

Investor Relations

1-888-381-7923

or

Brendan Brennan

Chief Financial Officer

+ 353 —1-291-2000

or

Sam Farthing

VP Investor Relations

+ 353 —1-291-2000

All at ICON.